Dergiler / Viral Hepatitis Journal / 2020 / Cilt: 26 - Sayı: 1

The Long-term (10.6 years) Outcome of Hepatitis C patients with Sustained Virologic Response Following Treatment with Pegylated Interferon + Ribavirin

Pegile Interferon + Ribavirin ile Tedavisi ile Kalıcı Virolojik Yanıt Elde Edilen Hepatit C Hastalarının Uzun Dönemli (10,6 yıl) Sonuçları

Sayfa
22–27
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

There should be a strict follow-up of cirrhotic patients, especially for HCC development.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Directly-acting anti-viral agents for the treatment of hepatitis C have been revolutionised.
📊
Temel Bulgular & Veri:Materials and Methods: One hundred thirty-five patients with hepatitis C virus who achieved SVR with pegylated INF alpha + RIB treatment between 2006 and 2010 are included in the study.
💡
Sonuç & Katkı:There should be a strict follow-up of cirrhotic patients, especially for HCC development.
🔬Tür:Araştırma Makalesi
📍Kapsam:2006 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

Objectives: Directly-acting anti-viral agents for the treatment of hepatitis C have been revolutionised. In the meantime, hepatitis C patients with sustained virologic response (SVR) achieved with previous treatments have been forgotten. Hepatitis C patients with SVR achived by pegylated interferon + ribavirin (INF + RIB) treatment are followed and it is investigated whether cirrhosis, hepatocellular carcinoma (HCC) and/or decompensation developed or not in these patients. Materials and Methods: One hundred thirty-five patients with hepatitis C virus who achieved SVR with pegylated INF alpha + RIB treatment between 2006 and 2010 are included in the study. At least twice a year, these patients were followed-up with ultrasonography, alpha fetoprotein and routine laboratory tests. Results: Out of the patients, 97.8% were genotype 1 and 95% were evaluated with biopsy before the treatment. One hundred twenty non-cirrhotic patients and 15 patients with compensated cirrhosis were followed for a period of 10.6 years (distribution: 9-13 years). None of the non-cirrhotic patients developed cirrhosis or HCC. HCC was developed in one of 15 cirrhotic patients (6 years after the treatment), resulting in the death of the patient. There were no decompensation case. Conclusion: It is evaluated that non-cirrhotic hepatitis C patients who achieved SVR with pegylated INF can be followed in a wider range of time. There should be a strict follow-up of cirrhotic patients, especially for HCC development.

Abstract

devrim yaratmıştır. Zamanla, önceki tedavilerle elde edilen kalıcı virolojik yanıtı (SVR) olan hepatit C hastaları unutulmuştur. Bu çalışmada Pegile interferon + ribavirin (INF + RIB) tedavisi ile SVR elde edilen hepatit C hastaları takip edilmiş ve bu hastalarda siroz, hepatoselüler karsinom (HCC) ve/veya dekompansasyon gelişip gelişmediği araştırılmıştır. Gereç ve Yöntemler: Çalışmada, 2006-2010 yılları arasında pegile INF alfa + RIB tedavisi ile SVR elde edilen 135 HCV hasta incelenmiştir. Bu hastalar yılda en az iki kez ultrasonografi, alfa fetoprotein ve rutin laboratuvar testleri ile takip edilmiştir. Bulgular: Hastalarımızın %97,8’i genotip 1 olup, %95’i tedavi öncesi biyopsi ile değerlendirilmiştir. Siroz olmayan 120 hasta ve kompanse sirozlu 15 hasta ortalama 10,6 yıl (dağılım: 9-13 yıl) takip edilmiştir. Siroz olmayan hastaların hiçbirinde siroz veya HCC gelişmemiştir. Sirozlu 15 hastanın 1’inde (tedaviden 6 yıl sonra) HCC gelişmiş ve bu hasta kaybedilmiştir. Dekompansasyon olgusu görülmemiştir. Sonuç: Pegile INF ile SVR elde edilen, siroz olmayan hepatit C hastalarının daha geniş zaman aralıklarında izlenebileceği değerlendirilmiştir. SVR’li sirotik hastalarının ise, özellikle HCC gelişimi açısından sıkı takibi yapılmalıdır.

🔖

Bu Makaleye Atıf Yap

ÖZDOĞAN, O., YARAŞ, S. (2020). The Long-term (10.6 years) Outcome of Hepatitis C patients with Sustained Virologic Response Following Treatment with Pegylated Interferon + Ribavirin. Viral Hepatitis Journal, Cilt: 26 - Sayı: 1, 22–27. https://ajindex.com/articles/332621

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018 69:461-511
  2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374
  3. Yu ML, Lin SM, Chuang WL, Dai CY, Wang JH, Lu SN, Sheen IS, Chang WY, Lee CM, Liaw YF. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: A nationwide, multicentre study in Taiwan. Antivir Ther. 2006;11:985-994
  4. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147:677-684
  5. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729-738
  6. Yoshida H, Arakawa Y, Sata M, Nishiguchi S, Yano E, Fujiyama S, Yamada G, Yokosuka O, Shiratori Y, Omata M. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483-491
  7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol. 2014;60:392-420
  8. Swain MG, Lai MY, Shiffman ML, Cooksley WG, Zeuzem S, Dieterich DT, Abergel A, Pessôa MG, Lin A, Tietz A. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology. 2010;139:1593-1601
  9. Moon C, Jung KS, Kim DY, Baatarkhuu O, Park JY, Kim BK, Kim SU, Ahn SH, Han KH. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin. Dig Dis Sci. 2015;60:573-581
  10. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with Hepatitis C who have sustained response to interferon therapy. Ann Int Med. 2000;132:517-524 11. Desmond CP, Roberts SK, Dudley F, Mitchell J, Day C, Nguyen S, Pianko S. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis